Akèy › Sipwa › Indiana › Indianapolis
Etid klinik pou Sipwa nan Indianapolis, IN
13 etid pou Sipwa ap chèche patisipan nan sit nan ak bò kote Indianapolis (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Ap rekriteFaz 3
- IU Health - Riley Physicians Endo-Diab, Indianapolis
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
Ap rekriteFaz 3
- Midwest Inst For Clin Res, Indianapolis
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
Ap rekriteFaz 3
- Midwest Inst For Clin Res, Indianapolis
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Ap rekriteFaz 3
- Indiana University Health University Hospital, Indianapolis
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Ap rekriteFaz 3
- Riley Hospital for Children, Indianapolis
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Ap rekriteFaz 3
- Indiana University Health University Hospital, Indianapolis
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Ap rekriteFaz 3
- DM Clinical Research - Indianapolis, Indianapolis
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Ap rekriteFaz 3
- AURORA-1 Clinical Site, Indianapolis
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Ap rekriteFaz 3
- AURORA-2 Clinical Site, Indianapolis
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Ap rekriteFaz 2
- Investigators Research Group, Brownsburg · 14 mi lwen
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Ap rekriteFaz 4
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
- The Indiana Clinical Trials Center, PC, Plainfield · 14 mi lwen
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
Ap rekriteFaz 3
- Midwest Inst For Clin Res, Indianapolis
Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
Ap rekrite
- Indiana University, Indianapolis
Etid Sipwa nan lòt vil
- San Antonio, TX34 etid
- Houston, TX33 etid
- Chicago, IL28 etid
- Orlando, FL27 etid
- Las Vegas, NV23 etid
- Miami, FL23 etid
- Atlanta, GA20 etid
- Dallas, TX20 etid
- New York City, NY19 etid
- Jacksonville, FL19 etid
- Washington, DC19 etid
- Austin, TX18 etid
Lòt etid nan Indianapolis
- Kansè Poumon ki pa ti selil32 etid
- Kansè (tout kalite)24 etid
- Ensifizyans kadyak23 etid
- Kansè nan tete20 etid
- Obèsite20 etid
- Kansè Metastatik19 etid
- Kansè kolorektal18 etid
- Kansè ovè17 etid
- Kansè poumon16 etid
- Maladi kadyovaskilè16 etid
- Dyabèt tip 114 etid
- Kansè Endomèt14 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.